Student Scientific Society, Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland.
Faculty of Medicine, Medical University of Warsaw, 02-091 Warszawa, Poland.
Int J Mol Sci. 2024 Jun 21;25(13):6844. doi: 10.3390/ijms25136844.
B-cell lymphoblastic leukemia is a hematologic neoplasm that poses a serious health concern in childhood. Genetic aberrations, such as mutations in the genes , , and or gene fusions involving ::, ::, and ::, often correlate with the onset of this disease. These aberrations can lead to malfunction of the JAK-STAT signaling pathway, which is implicated in various important biological processes, including those related to immunology. Understanding the mechanisms underlying the malfunction of the JAK-STAT pathway holds potential for research on drugs targeting its components. Available drugs that interfere with the JAK-STAT pathway include fludarabine, ruxolitinib, and fedratinib.
B 细胞淋巴母细胞白血病是一种血液系统恶性肿瘤，在儿童中构成严重的健康威胁。遗传异常，如 、 、 和 基因的突变，或涉及 :: 、 :: 和 :: 的基因融合，常与该病的发生相关。这些异常可导致 JAK-STAT 信号通路的功能障碍，该通路涉及许多重要的生物学过程，包括免疫学相关过程。了解 JAK-STAT 通路功能障碍的机制可能有助于针对其成分的药物研究。现有的干扰 JAK-STAT 通路的药物包括氟达拉滨、鲁索利替尼和 fedratinib。
